Author: admin

Andrew Hanson Vice President of Generations Wealth Management Interviewed on the Influential Entrepreneur Podcast Discussing Finding the Right Investment Vehicle

Andrew Hanson discusses finding the right investment vehicle

Listen to the interview on the Business Innovators Radio Network: https://businessinnovatorsradio.com/interview-with-andrew-hanson-vice-president-of-generations-wealth-management-discussing-finding-the-right-investment-vehicle/

Andrew Hanson, Vice President of Generations Wealth Management, discusses the importance of selecting the right investment vehicles for retirement. Andrew shares his unique journey into the financial services industry, which began eight years ago when he joined his family business. Despite initially feeling hesitant about entering a field dominated by numbers, Andrew’s passion for community service and helping others, shaped by his volunteer work with Special Olympics and connections with military families in San Clemente, California, guided him toward a fulfilling career in finance.

Building a strong relationship and understanding clients’ individual goals is crucial for providing tailored investment advice and solutions. In the podcast episode featuring Andrew, this concept is emphasized as a foundational element of successful financial advising.

Andrew highlights that establishing trust is essential in the financial services industry. Clients often come in feeling vulnerable, sharing their financial situations and concerns. A competent advisor must create an environment where clients feel safe and understood. This trust allows clients to open up about their fears and aspirations, which is vital for crafting personalized financial strategies.

Each client has unique circumstances, goals, and concerns. Andrew points out that a one-size-fits-all approach does not work in financial planning. For instance, younger clients in their 30s and 40s may focus on budgeting, family planning, and long-term growth, while clients in their 60s and 70s may prioritize security, income stability, and legacy planning. By understanding these differences, advisors can tailor their recommendations to meet specific needs.

Initial meetings with clients should focus on understanding their overall goals and what they envision for their future. Andrew emphasizes the importance of asking clients about their dreams, such as spending time with grandchildren or traveling. This goal-oriented approach helps advisors align investment strategies with clients’ life aspirations, ensuring that the financial plan supports their desired lifestyle.

Once an advisor understands a client’s goals, they can recommend investment vehicles that align with those objectives. For example, Andrew discusses the use of fixed index annuities, which can be tailored to address specific concerns such as long-term care, income guarantees, or wealth transfer to heirs. This customization is only possible when the advisor has a deep understanding of the client’s individual situation.

Building a relationship with clients is not a one-time effort; it requires ongoing communication and check-ins. Andrew notes that as clients become more comfortable, they may prefer less frequent updates, trusting their advisor to manage their investments effectively. This dynamic allows for a more relaxed relationship while still ensuring that the advisor remains attuned to any changes in the client’s life or goals.

Life circumstances can change, and so can clients’ goals. A strong relationship allows advisors to adapt their strategies as needed. For instance, if a client’s financial situation changes due to a job loss or a new family member, the advisor can reassess and adjust the investment plan accordingly.

Andrew shared: “As a trusted family-owned firm, we blend our deep-rooted values of integrity, trust, and reliability with innovative financial expertise. With a commitment to excellence, we strive to be the beacon of financial stability for generations to come, fostering prosperity and peace of mind within the families we serve”

Video Link: https://www.youtube.com/embed/2kzHIL137G4

About

Two generations of trusted Hanson financial professionals serve multiple generations of clients concerned with financial goals, wealth management, safety, security, and estate planning. Richard Hanson, President of Generations Financial & Insurance Services, began his career in 1983. He is currently an educational speaker on retirement and money management. Mr. Hanson is Designated as a Certified Senior Advisor (CSA). He Currently Holds a membership with the National Association of Life Underwriters. 2011 Insurmark Hall of Fame Inductee. Andrew Hanson, Vice President of Generations Financial began his career in January 2016. He is the Head of Case Design Team & Digital Outreach. He hosts numerous Seminars educating our community on such subjects as; Social Security, RMD’s, Asset Protection, Legacy Protection, College Funding and IRA / 401(k) Analysis.

Learn more: https://www.generationswealthmgt.com/

Recent Interviews and News

Richard Hanson discusses financial confidence in retirement: Richard Hanson President of Generations Wealth Management Interviewed on the Influential Entrepreneur Podcast Discussing Financial Confidence in Retirement

Richard Hanson discusses living retirement to the fullest: Richard Hanson President of Generations Wealth Management Interviewed on the Influential Entrepreneur Podcast Discussing Living Retirement to the Fullest

Richard Hanson discusses overcoming fears of market volatility: Richard Hanson President of Generations Wealth Management Interviewed on the Influential Entrepreneur Podcast Discussing Overcoming Fears of Market Volatility

Media Contact
Company Name: Marketing Huddle, LLC
Contact Person: Mike Saunders, MBA
Email: Send Email
Phone: 7202323112
Country: United States
Website: https://www.AuthorityPositioningCoach.com

Jake Smolarek Unveils the Impact of Business Coaching on Strategic Financial Decisions

When you think about improving your company’s financial decisions, your mind might go to spreadsheets, forecasting software or maybe just that last-minute call to your accountant. But have you ever considered bringing in a business coach? As I found out in a chat with Jake Smolarek, London’s Best Life and Business Coach, there’s a whole world of clarity, strategy and transformation that coaching can bring to the table – and to your bank balance.

Jake has helped many leaders untangle the mess of decision making. “Think of me as your financial GPS” he said with a smile during our chat.

So, how does a business coach give leaders an edge in financial decision-making? Let’s get into it.

Clarity, Strategy and Smarter Risk Management

What keeps leaders up at night? Uncertainty. The question isn’t just “What should I invest in?” but also “What if it goes wrong?” This is where the magic of business coaching comes in.

“Good financial decisions start with good leadership decisions,” said Smolarek. “Coaching helps leaders untangle the emotions tied to financial risk and replace them with clear, actionable strategy”.

Take risk management, for example. A business coach can help leaders understand not just the numbers but the mindset behind risk. When you’re clear on your goals, your appetite for risk becomes strategic—not just a roll of the dice. With this clarity, leaders often find themselves making bold but informed decisions that deliver long-term results.

In one example, Jake shared that a client was frozen with fear when considering expanding into a new market. By breaking it down into smaller steps, weighing up the risks against the rewards, and focusing on long-term goals, they were able to move forward. The result? 30% revenue growth in the first year of expansion. Not bad for a move that seemed like leaping into the unknown.

The Research Behind Coaching and Financial Mastery

You might be thinking: Is there any research to back this up? Yes.

Research shows that decision fatigue – a common problem for leaders – is significantly reduced when there is a clear framework for solving problems. Coaching provides this framework. It’s not just about accountability (although that’s a big part of it); it’s also about rewiring your brain to prioritise, analyse and act with precision.

One of the most fascinating concepts in neuroscience is neuroplasticity – the brain’s ability to rewire itself based on new experiences. Through regular coaching sessions, leaders develop new problem-solving pathways in their brains. Over time this leads to faster, more confident decision making.

“The brain is like a muscle,” Jake said. “The more you train it with strategic thinking, the stronger it gets. And when it comes to financial decisions, mental strength is everything“.

Another key part is emotional regulation. Research in behavioural finance shows that emotional bias clouds decision making and leads to poor financial outcomes. Coaching helps leaders identify these biases and address them before they happen. Whether it’s fear of loss or overconfidence a coach is a sounding board to keep emotions in check.

Action Steps: Better Financial Decisions

Ready to level up your financial game? Here are a few things you can start doing today:

  1. Audit Your Assumptions: Before making any financial decision, question your assumptions. Are they based on fear or fact? A coach can help you see the blind spots.
  2. Set Clear Financial Goals: You can’t make good decisions without a destination in mind. Work with your coach to define what success looks like.
  3. Use Data – But Don’t Drown in It: Numbers are important, but analysis paralysis is real. Learn to find the balance with the help of an experienced coach.
  4. Review Past Decisions: A quick debrief on previous financial calls will reveal patterns. Did you hesitate too much? Were you too aggressive? Reflection is key to growth.
  5. Role Play Scenarios: Jake recommends simulating high stakes decisions in a low stakes environment. “Practice makes perfect – even for financial calls,” he said.

These might seem simple, but the power lies in consistency.

Coaching Meets Strategy: Investment Decisions with a Twist

Nowhere is the impact of coaching more visible than in investment strategy. Leaders are bombarded with conflicting advice, data overload and the fear of losing money. Enter the business coach.

A professional business coach helps leaders weigh not just ROI but also alignment to long-term goals. Focusing on the bigger picture makes leaders less likely to be swayed by short-term market trends or emotional decision-making. “Investments should feel like stepping stones not tightropes“, Jake said.

One of Jake’s clients was torn between investing in new technology or sticking with their current infrastructure. By working through a coaching session that covered scenarios, timelines and ROI they made a decision. Result? A more streamlined operation and a competitive advantage in their market.

Looking to sharpen your edge? Jake Smolarek, the UK’s top Business Coach, is the man.

Why Business Coaching is an Essential Investment

At the end of the day, business coaching isn’t just about making better financial decisions. It’s about changing the way you think about leadership, risk and strategy. As Smolarek says, “A strong financial strategy isn’t just numbers on a page; it’s the confidence to make the tough calls and the wisdom to know when to pivot“.

Coaching also brings accountability, which is missing in self-led decision-making. When you’re reporting to someone who really cares about your growth, there’s a higher chance you’ll follow through on plans and promises. That alone can make a big difference in financial outcomes.

So why not take the plunge? Work with a coach who gets the numbers and the human side of decision-making. As Jake would say “The best investment you can make is in your own ability to lead”.

Still not convinced? Try this final piece of advice from Jake: “Think of coaching as a cheat code – but one that helps you build your own skills so you won’t need me forever“. With the proper guidance, your financial decisions can go from reactive to proactive, from hesitant to confident and from mediocre to extraordinary.

Media Contact
Company Name: Jake Smolarek LTD
Contact Person: Jake Smolarek
Email: Send Email
City: London
Country: United Kingdom
Website: https://jakesmolarek.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Jake Smolarek Unveils the Impact of Business Coaching on Strategic Financial Decisions

Kradle.io Launches: A Revolutionary SaaS Platform for Modern Property Management

Kradle.io, a pioneering SaaS platform, is officially launched today, offering an innovative solution designed to redefine property management.

December 23, 2024 – Kradle.io, a pioneering SaaS platform, is officially launched today, offering an innovative solution designed to redefine property management. With a focus on enhancing security, usability, and comprehensive support, Kradle.io is set to provide an unparalleled management experience for landlords, tenants, and property managers.

Key Features of Kradle.io:

  • Dashboard: An interactive dashboard provides property managers with a comprehensive real-time view of their properties, enhancing task management and workflow efficiency.
  • Property Management: Efficient tools for tracking tenants and managing contracts streamline the complexities of property management.
  • Maintenance Management: A robust system for logging and addressing maintenance requests includes automatic updates to ensure all parties are informed promptly.
  • Payment Processing: A secure, flexible payment system facilitates easy management of financial transactions.
  • Calendar: Essential dates such as lease renewals and maintenance schedules are easily managed through an integrated calendar.
  • Messaging: A sophisticated messaging system fosters clear and prompt communication between tenants and landlords.
  • Leasing Management: Streamline the leasing process with automated handling of documents and e-signatures, significantly reducing paperwork and saving valuable time.

 

What’s Ahead for Kradle.io?

  • AI-powered Predictive Maintenance: Advanced AI tools will predict maintenance needs before they become issues.
  • Blockchain for Enhanced Security: We’re boosting security with blockchain technology, making every transaction transparent and secure.
  • Advanced Tenant Screening: We are refining our tenant screening processes to ensure landlords can easily find and select the best tenants.
  • Simplified Rent and Eviction Management: We’re streamlining how rent is collected and evictions are managed, simplifying these essential tasks.
  • Community and Wellness Initiatives: Recognizing the importance of community, we are introducing programs designed to enhance tenant well-being and community engagement.

 

Our Mission:

“At Kradle, we aim to provide a rental experience that feels safe, supportive, and straightforward, guiding tenants and landlords smoothly from the start of a lease to its conclusion.”

Kradle.io isn’t just a tool; it’s a comprehensive partner in property management. As we forge ahead, Kradle.io continues to innovate, enhancing how property management is conducted. Visit www.kradle.io to see how we can transform your property management experience.

Join the revolution in property management with Kradle.io – Your partner in redefining the rental landscape.

Media Contact
Company Name: Kradle.io
Contact Person: Bishoy Girgis
Email: Send Email
Phone: 732-816-5059
Address:35 Equestrian Way
City: Monroe
State: New Jersey
Country: United States
Website: https://kradle.io

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Kradle.io Launches: A Revolutionary SaaS Platform for Modern Property Management

Omer B Announces the Release of New Instrumental Single “Dino Puppy Groove”

New track blends diverse musical influences into an optimistic soundscape.

Independent musician and guitarist Omer B is pleased to announce the official release of his latest instrumental single, “Dino Puppy Groove,” now available through all major streaming platforms and social media channels. The track aims to provide listeners with an uplifting and distinctive musical experience that draws on a wide range of genres, including funk, rock, blues, gospel, pop, and jazz.

The new single marks a notable moment in Omer B’s evolving career as a musician who seamlessly integrates eclectic influences into a coherent and engaging style. “Dino Puppy Groove” reflects a joyful and open-hearted mood, offering a sound described as both bright and energetic. The title pays subtle homage to two well-regarded bands, Snarky Puppy and Chalk Dinosaur, both of which have inspired Omer B’s approach to crafting a fresh and dynamic musical landscape.

Recorded and produced to highlight the versatility of Omer B’s instrumentation, “Dino Puppy Groove” features his guitar and bass work complemented by the driving percussion of drummer Glenn Welwman. The result is an arrangement that balances technical skill with a clear intent to spark positivity. From the first note, the track encourages an optimistic outlook, suggesting that music can serve as a refreshing escape as well as a source of comfort.

Available on Apple Music, Spotify and through DistroKid, the single invites listeners to experience the natural synthesis of different musical traditions. Omer B hopes that this piece will appeal to fans of diverse genres, while also attracting new audiences who value authentic artistic expression.

Omer B commented on the new release, “I wanted to create something that radiates warmth and hope, something that feels as playful as it is heartfelt. ‘Dino Puppy Groove’ is about embracing the natural blend of influences that come together in my music.”

A longtime supporter of Omer B’s work, listener James Carter, remarked on the single, “This track is a reminder that music can transcend categories. It captures so much joy while remaining grounded in a rich and honest sound.”

For more information visit https://www.omerb.net.

About Omer B

Omer B is an independent musician and amateur race driver who has cultivated a sound that draws from multiple genres and influences. He has consistently focused on producing music that feels both exploratory and accessible. With a background that includes funk, rock, blues, gospel, pop, and jazz, Omer B aims to create pieces that connect with listeners on a personal level.

Media Contact
Company Name: Omer B
Contact Person: Omer B
Email: Send Email
Country: United States
Website: https://www.omerb.net

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Omer B Announces the Release of New Instrumental Single “Dino Puppy Groove”

Synovial Sarcoma Therapeutics Market Size in the 7MM is expected to increase by 2034, estimates DelveInsight

DelveInsight’s “Synovial Sarcoma Market Insights, Epidemiology, and Market Forecast–2034” report delivers an in-depth understanding of synovial sarcoma, historical and forecasted epidemiology as well as the synovial sarcoma market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

 

Discover Key Insights into the Synovial Sarcoma Market with DelveInsight’s In-Depth Report @ Synovial Sarcoma Market Size

 

Key Takeaways from the Synovial Sarcoma Market Report

  • Among the 7MM, the US accounted for the highest incident cases of synovial sarcoma in 2023, with around 650 cases; these cases are expected to increase during the forecast period.
  • In 2023, the total number of incident cases of synovial sarcoma in EU4 and the UK was highest in Germany, while the lowest number of cases was in Spain.
  • In cases of gender-specific synovial sarcoma, males are observed to be the predominant contributors compared to females.
  • As per DelveInsight’s estimates, the highest incidence of Synovial Sarcoma in Japan is in Stage II which has ~100 cases in 2023 that are projected to increase during the forecast period.
  • The leading Synovial Sarcoma Companies such as Takara Bio Inc., Foghorn Therapeutics Inc., Onco Therapy Science Inc., C4 Therapeutics Inc., Adaptimmune, Advenchen Laboratories LLC, Epizyme Inc., GlaxoSmithKline, Ipsen, Bayer, Eli Lilly and Company, Sumitomo Pharma Oncology Inc., and others.
  • Promising Synovial Sarcoma Pipeline Therapies such as CFT8634, FHD-609, Afamitresgene autoleucel, AL3818, Itacitinib, CAB-AXL-ADC, TP-1287, APX005M, Tazemetostat, and others.

 

Navigate the complexities of the Synovial Sarcoma Market: gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Synovial Sarcoma Market Forecast. Click here to get more insights @ Synovial Sarcoma Treatment Market

 

Synovial Sarcoma Epidemiology Segmentation in the 7MM

  • total Synovial Sarcoma Incident cases
  • Synovial Sarcoma Gender-specific cases
  • Synovial Sarcoma Age-specific cases
  • Synovial Sarcoma Location-specific cases
  • Synovial Sarcoma Stage-specific cases
  • Synovial Sarcoma Antigen-specific (MAGE-A4, NY-ESO-1, PRAME, and others) cases
  • Synovial Sarcoma line-wise treated patient pool

 

Download the report to understand which factors are driving Synovial Sarcoma epidemiology trends @ Synovial Sarcoma Prevalence

 

Synovial Sarcoma Marketed Drugs

  • TECELRA (afamitresgene autoleucel): Adaptimmune Therapeutics

TECELRA (afami-cel; formerly ADP-A2M4) is a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices. In August 2024, Adaptimmune Therapeutics received the US FDA accelerated approval of TECELRA for the treatment of adults with unresectable or metastatic synovial sarcoma. The approval of TECELRA was based on results of the SPEARHEAD-1 (Cohort 1) trial. TECELRA treatment resulted in an ORR of 43% with a complete response rate of 4.5%. TECELRA is the first engineered cell therapy for solid tumors. Also, it is the first new treatment option for synovial sarcoma in more than a decade. Sarcoma centers of excellence across the Unites States are being onboarded as Authorized Treatment Centers (ATCs) for TECELRA.

 

Synovial Sarcoma Emerging Drugs

  • Letetresgene autoleucel (lete-cel): Adaptimmune Therapeutics

Letetresgene autoleucel is an engineered TCR T-cell therapy targeting the solid tumor antigen NY-ESO-1. Lete-cel is being investigated for the treatment of synovial sarcoma and myxoid/round cell liposarcoma (MRCLS) in the pivotal IGNYTE-ESO (NCT03967223) trial in patients who received prior anthracycline treatment. Sponsorship of the ongoing clinical trials for lete-cel has transitioned from GSK to Adaptimmune. The IGNYTE-ESO trial, which is ongoing but no longer open for new participants, has had its interim analysis data presented at CTOS in 2023 also reported data for sub-study 1 of the IGNYTE-ESO trial which explores lete-cel in the first-line setting for treatment naïve patients with metastatic or unresectable synovial sarcoma or MRCLS. The company plans to launch lete-cel commercially in the US by 2026. This will be the second product in the sarcoma portfolio, targeting both synovial sarcoma and MRCLS, thereby significantly broadening treatment options for these cancers.

 

  • AL3818 (anlotinib): Advenchen Laboratories

AL3818 is an orally administered receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR1, VEGFR2/KDR, and VEGFR3), stem cell factor receptor (C-kit), platelet-derived growth factor (PDGFβ), and fibroblast growth factor receptors (FGFR1, FGFR2, and FGFR3). AL3818 is being evaluated for the treatment of alveolar soft part sarcoma, leiomyosarcoma, and synovial sarcoma in a global Phase III trial. It is being developed by Advenchen Laboratories. The FDA and EMA granted AL3818 an orphan drug designation for the potential treatment of soft tissue sarcomas.

 

Get In-Depth Knowledge on Synovial Sarcoma Market Trends and Forecasts with DelveInsight @ Synovial Sarcoma Treatment Market

 

Synovial Sarcoma Market Outlook

Surgery remains the primary and only curative treatment for localized, resectable soft tissue sarcomas (STS), including synovial sarcoma, typically combined with radiotherapy. In terms of pharmacological therapies, which are the focus of market forecasts by DelveInsight, chemotherapy is the mainstay for metastatic sarcomas. For synovial sarcoma, the standard approach involves a fixed number of chemotherapy cycles with doxorubicin and ifosfamide as the first-line drugs, generating significant revenue in this field. YONDELIS, an antitumor agent, is approved in Europe for advanced soft tissue sarcoma after failure of standard therapies or in patients unable to receive them. However, its effectiveness for synovial sarcoma in the US remains uncertain. VOTRIENT, an oral multi-target tyrosine kinase inhibitor, is currently the only TKI approved for various STS subtypes, including synovial sarcoma. It works by inhibiting VEGFR-mediated angiogenesis and blocking receptor tyrosine kinases involved in tumor growth.

 

Synovial Sarcoma Treatment Market Landscape

The treatment plan for synovial sarcoma is tailored to the individual patient. The type of treatment that is usually depend on size and location of the tumor, the patient’s age and overall health, and patient’s preference. The goal of the treatment for synovial sarcoma is to cure the cancer. However, not all patients are cured. In some may come back. If the cancer comes back, it may be treated with surgery, radiation therapy, chemotherapy, or targeted therapy. As per latest treatment paradigms chemotherapy regimen is administered for a fixed number of cycles followed by a watchful waiting approach to assess the optimum response. Doxorubicin and Ifosfamideconstitute the first line approach thereby helping generate a large chunk of the revenue.

 

Gain a strategic edge in the Synovial Sarcoma Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Synovial Sarcoma Market Forecast. Click here to lead in advancements @ Synovial Sarcoma Clinical Trials Assessment

 

Scope of the Synovial Sarcoma Market Report

  • Coverage- 7MM
  • Study Period- 2020-2034
  • Synovial Sarcoma Companies- Takara Bio Inc., Foghorn Therapeutics Inc., Onco Therapy Science Inc., C4 Therapeutics Inc., Adaptimmune, Advenchen Laboratories LLC, Epizyme Inc., GlaxoSmithKline, Ipsen, Bayer, Eli Lilly and Company, Sumitomo Pharma Oncology Inc., and others.
  • Synovial Sarcoma Pipeline Therapies- CFT8634, FHD-609, Afamitresgene autoleucel, AL3818, Itacitinib, CAB-AXL-ADC, TP-1287, APX005M, Tazemetostat, and others.
  • Synovial Sarcoma Market Dynamics: Synovial Sarcoma Market Drivers and Barriers
  • Synovial Sarcoma Therapeutic Assessment: Synovial Sarcoma Current marketed and Synovial Sarcoma Emerging Therapies

 

Table of Content

1. Key Insights

2. Synovial Sarcoma Executive Summary

3. Competitive Intelligence Analysis for Synovial Sarcoma

4. Synovial Sarcoma: Market Overview at a Glance

5. Synovial Sarcoma: Disease Background and Overview

6. Synovial Sarcoma Patient Journey

7. Synovial Sarcoma Epidemiology and Patient Population

8. Synovial Sarcoma Treatment Algorithm, Current Treatment, and Medical Practices

9. Synovial Sarcoma Unmet Needs

10. Key Endpoints of Synovial Sarcoma Treatment

11. Synovial Sarcoma Marketed Products

12. Synovial Sarcoma Emerging Therapies

13. Synovial Sarcoma: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Synovial Sarcoma Market Outlook

16. Synovial Sarcoma Market Access and Reimbursement Overview of Synovial Sarcoma

17. Synovial Sarcoma KOL Views

18. Synovial Sarcoma Market Drivers

19. Synovial Sarcoma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Synovial Sarcoma Therapeutics Market Size in the 7MM is expected to increase by 2034, estimates DelveInsight

FYZICAL Therapy & Balance Centers Adds Vestibular Services to Benefit the Coral Springs Community

New Vestibular treatments led by Ray Masse, Available for Appointments starting 1/30/25

FYZICAL Therapy & Balance Center Coral Springs, part of the country’s fastest-growing physical therapy franchise and leader in balance therapies, announced today the addition of Vestibular treatments to its physical therapy services. With growing demand for services that address balance and fall risks, FYZICAL Coral Springs will begin offering appointments on 1/30/25 with Ray Masse.

“We’ve seen an increasing need for fall risk prevention in the Coral Springs area, and we look forward to meeting the needs of our local community,” said clinic liaison Ari Vinograd. “Our seasoned physical therapists are specially trained to treat issues related to fall risks, so new and familiar patients can rest assured that they are getting the best possible care, allowing them to live and love their life to the fullest.”

With a unique roof-harness system used to keep patients safely suspended during treatment, Fyzical’s seniors and balance patients are afforded additional peace of mind while moving towards their wellness goals. Their balance programs have a wide variety of health benefits, including the reducing the risk of falling injuries, maintaining independence with daily activities, improving strength, pain-reduction, flexibility, mobility, addressing dizziness, and improving vision stability.

FYZICAL Therapy & Balance Center Coral Springs offers a wide variety of services designed to address a broad range of diagnoses, conditions and concerns, including dizziness, balance and neurologic issues, and pelvic health. The center also offers an orthopedic rehabilitation program that helps patients reduce and reverse orthopedic pain or immobility.

FYZICAL Therapy & Balance Center Coral Springs has been serving the Coral Springs community since 2022. For more information about FYZICAL Coral Springs, visit https://www.fyzical.com/coral-springs-fl or https://g.co/kgs/kghq9V7

About FYZICAL Therapy & Balance Centers:

FYZICAL Therapy & Balance Centers stands at the forefront of the health and wellness industry as the nation’s fastest-growing physical therapy franchise, boasting an extensive network of over 575 locations that span across 46 states. Committed to a holistic approach, FYZICAL provides top-notch, personalized care plans to treat patients of all ages experiencing muscle, joint, and neurological conditions including balance and vestibular issues. As an advocate for patient choice and direct access, FYZICAL empowers individuals to take control of their well-being to achieve optimal physical health and balance.

Media Contact
Company Name: FYZICAL Therapy & Balance Center Coral Springs
Contact Person: Ari Vinograd
Email: Send Email
Phone: (954) 779-4549
Country: United States
Website: https://www.fyzical.com/coral-springs-fl

Stargardt Disease Therapeutics Market Size in the 7MM was ~USD 27 million in 2023, which is expected to increase by 2034, estimated DelveInsight

DelveInsight’s “Stargardt Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Stargardt Disease, historical and forecasted epidemiology as well as the Stargardt Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Discover Key Insights into the Stargardt Disease Market with DelveInsight’s In-Depth Report @ Stargardt Disease Market Size

 

Key Takeaways from the Stargardt Disease Market Report

  • Among the 7MM, the United States accounted for the highest number of diagnosed prevalent cases of Stargardt, which is 43.0% of the diagnosed-incident cases of Stargardt in 2023.
  • In the US, out of all age groups, the highest onset age-specific cases accounted for >20 years, followed by 20-39 years in 2020. In contrast, the least onset age-specific cases were observed in =60 years age groups.
  • Among the EU4 and the UK, Germany accounted for the highest number of Stargardt Disease cases, followed by the UK, whereas Spain accounted for the lowest number of prevalent cases.
  • In Japan, the highest symptoms-specific cases of Symptomatic Stargardt Disease were for reduced vision, followed by Nyctalopia, Photophobia, and other cases, respectively, in 2023.
  • The leading Stargardt Disease Companies such as Ocugen, Kubota Vision Inc, Nanoscope Therapeutics Inc., RBP4 Pty Ltd, Stargazer Pharmaceuticals, Inc., Belite Bio, Inc, Alkeus Pharmaceuticals, Inc., IVERIC bio, Inc., Kubota Vision Inc., Astellas Institute, Nanoscope Therapeutics, Alkeus Pharmaceuticals, and others
  • Promising Stargardt Disease Therapies such as OCU410ST, Emixustat, Gene Therapy-vMCO-010, tinlarebant, STG-001, Tinlarebant, ALK-001, Zimura, Emixustat, MA09-hRPE, MCO-010 (Sonpiretigene Isteparvovec), ALK-001 (Gildeuretinol), and others

 

Navigate the complexities of the Stargardt Disease Market: gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Stargardt Disease Market Forecast. Click here to get more insights @ Stargardt Disease Treatment Market

 

Stargardt Disease Epidemiology Segmentation in the 7MM

  • Stargardt Disease Diagnosed prevalent cases
  • Stargardt Disease Onset-age specific cases
  • Stargardt Disease Type-specific cases
  • Stargardt Disease Symptom-specific and treated cases

 

Download the report to understand which factors are driving Stargardt Disease epidemiology trends @ Stargardt Disease Prevalence

 

Emerging Stargardt Disease Therapies

  • Emixustat: Kubota Pharmaceuticals

Emixustat, developed by Kubota Pharmaceuticals, is an oral drug initially designed to target the dry form of age-related macular degeneration. It functions by slowing the buildup of toxic waste products that contribute to retinal degeneration in various retinal conditions, including Stargardt disease. The mechanism of action involves the modulation of the visual cycle by inhibiting a critical enzyme in this pathway, Retinal pigment epithelium-specific 65 kDa protein (RPE65). By slowing the visual cycle, Emixustat reduces the availability of vitamin A derivatives (11-cis-and all-trans-retinal) to form precursors of A2E and related compounds. In animal models of Stargardt disease and retinal degeneration, Emixustat has demonstrated the ability to decrease the accumulation of A2E and protect the retina from light-induced damage.

 

  • MCO-010: Nanoscope Therapeutics

Nanoscope’s MCO-010 is an optogenetic gene therapy that utilizes a convenient and well-established intraocular injection to deliver a gene encoding the ambient light-sensitive MCO protein into retinal cells. Multi-Characteristic Opsin (MCO) re-sensitize the retina for detecting low light levels to restore vision in blind patients, specifically for the treatment of Stargardt disease, with the goal of improving visual function.

 

Stargardt Disease Market Outlook

Stargardt disease is a rare genetic eye disease that occurs when fatty material builds up on the macula, the small part of the retina responsible for sharp, central vision. It is caused by a mutation in the ABCA4 gene (also caused by other genes in some instances), which prevents the production of a protein that cleans up the fatty material left over from vitamin A metabolism. As a result, the fatty material accumulates in yellowish clumps on the macula, eventually killing the light-sensitive cells and destroying central vision. Many new molecules with novel mechanisms, like emixustat, gildeuretinol, tinlarebant, avacincaptad pegol, among others, and gene therapies like MCO-010 and others, are being developed for the treatment of Stargardt disease by key players like Kubota Vision, Nanoscope Therapeutics, Alkeus Pharmaceuticals, Belite Bio, Astellas Pharma among others.

 

Get In-Depth Knowledge on Stargardt Disease Market Trends and Forecasts with DelveInsight @ Stargardt Disease Treatment Market

 

Stargardt Disease Therapies and Companies

  • OCU410ST: Ocugen
  • Emixustat: Kubota Vision Inc
  • Gene Therapy-vMCO-010: Nanoscope Therapeutics Inc.
  • tinlarebant: RBP4 Pty Ltd
  • STG-001: Stargazer Pharmaceuticals, Inc.
  • Tinlarebant: Belite Bio, Inc
  • ALK-001: Alkeus Pharmaceuticals, Inc.
  • Zimura: IVERIC bio, Inc.
  • Emixustat: Kubota Vision Inc.
  • MA09-hRPE: Astellas Institute
  • Emixustat : Kubota Pharmaceuticals
  • MCO-010 (Sonpiretigene Isteparvovec): Nanoscope Therapeutics
  • ALK-001 (Gildeuretinol): Alkeus Pharmaceuticals

 

Stargardt Disease Market Strengths

  • Stargardt Disease has a well-identified genetic basis, primarily associated with mutations in the ABCA4 gene, allowing for targeted research and potential therapeutic interventions.
  • Regulatory agencies, such as the FDA, recognize Stargardt Disease as an orphan disease, providing incentives for the development of orphan drugs and accelerated approval pathways.

 

Stargardt Disease Market Opportunities

  • Ongoing research in gene therapies, pharmacological interventions, and emerging technologies provides opportunities for the development of novel and effective treatments.
  • Rapid advancements in genetic technologies, including CRISPR-Cas9, offer potential breakthroughs in gene editing and correction of ABCA4 mutations

 

Gain a strategic edge in the Stargardt Disease Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Stargardt Disease Market Forecast. Click here to lead in advancements @ Stargardt Disease Clinical Trials Assessment

 

Scope of the Stargardt Disease Market Report

  • Study Period: 2020–2034
  • Coverage: 7MM
  • Stargardt Disease Companies: Ocugen, Kubota Vision Inc, Nanoscope Therapeutics Inc., RBP4 Pty Ltd, Stargazer Pharmaceuticals, Inc., Belite Bio, Inc, Alkeus Pharmaceuticals, Inc., IVERIC bio, Inc., Kubota Vision Inc., Astellas Institute, Nanoscope Therapeutics, Alkeus Pharmaceuticals, and others
  • Stargardt Disease Therapies: OCU410ST, Emixustat, Gene Therapy-vMCO-010, tinlarebant, STG-001, Tinlarebant, ALK-001, Zimura, Emixustat, MA09-hRPE, MCO-010 (Sonpiretigene Isteparvovec), ALK-001 (Gildeuretinol), Zimura, and others
  • Stargardt Disease Therapeutic Assessment: Stargardt Disease current marketed and Stargardt Disease emerging therapies
  • Stargardt Disease Market Dynamics: Stargardt Disease market drivers and Stargardt Disease market barriers
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Stargardt Disease Unmet Needs, KOL’s views, Analyst’s views, Stargardt Disease Market Access and Reimbursement

 

Table of Contents

1. Stargardt Disease Market Report Introduction

2. Executive Summary for Stargardt Disease

3. SWOT analysis of Stargardt Disease

4. Stargardt Disease Patient Share (%) Overview at a Glance

5. Stargardt Disease Market Overview at a Glance

6. Stargardt Disease Disease Background and Overview

7. Stargardt Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Stargardt Disease

9. Stargardt Disease Current Treatment and Medical Practices

10. Stargardt Disease Unmet Needs

11. Stargardt Disease Emerging Therapies

12. Stargardt Disease Market Outlook

13. Country-Wise Stargardt Disease Market Analysis (2020–2034)

14. Stargardt Disease Market Access and Reimbursement of Therapies

15. Stargardt Disease Market Drivers

16. Stargardt Disease Market Barriers

17. Stargardt Disease Appendix

18. Stargardt Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Stargardt Disease Therapeutics Market Size in the 7MM was ~USD 27 million in 2023, which is expected to increase by 2034, estimated DelveInsight

Juleani is on a Mission to Empower Women and Change the World with Stunning, Strong Jewelry

The Juleani team discusses their waterproof, lifetime wear jewelry and what the future holds.

Juleani is empowering women and changing the world with its line of luxury, affordable, lifetime wear jewelry.

Juleani’s founder created her company with a multi-faceted mission. Through Juleani, the team is empowering women not only with a lineup of stunning, durable jewelry but also by donating a portion of sales to Women’s World Banking, a global non-profit that uplifts women through financial inclusion. When women shop at Juleani, they are pouring into their own cups and also helping other women do the same.

When it comes to the jewelry, Juleani is unmatched in quality and price point. Featuring leading-edge PVD coating technology, which is now being implemented by the world’s leading luxury jewelry brands, Juleani offers women everywhere a budget-friendly option for gorgeous waterproof jewelry that can be worn every day for years to come. Aside from the coating technology, the jewelry itself is made to last. For instance, strong clasps ensure waterproof, sweatproof, lotionproof, scratchproof, and lifeproof wear.

Women can expect to find an expansive selection of carefully curated pieces among the first collections released by Juleani. Bridging the gap between luxury jewelry and affordability, women can find a budget-friendly and stunning selection of jewelry including bracelets, chains, earrings, and rings that can be worn around the clock, on the go, doing the dishes, showering, working out, and everything in between. Plus, everything is packaged in plastic-free and sustainable packaging to reduce the carbon footprint.

Juleani also has exciting plans to grow over the coming months and years. Soon, women will be able to choose from pre-designed Lifeproof Packs featuring a perfectly pre-styled set of items and classics for solo wear. Juleani plans to launch pop ups, design collaborations with strong female leaders, and more in the coming years. Stay up to date with this on-the-move company by visiting https://juleani.com/.

ABOUT JULEANI

Juleani offers timeless, premium, waterproof jewelry for everyday wear backed by a lifetime color guarantee. Follow on social media:

Instagram: @shopjuleani

Media Contact
Company Name: Juleani
Email: Send Email
Country: United States
Website: https://juleani.com/

Primary Hyperoxaluria Therapeutics Market Size in the 7MM was ~USD 316 million in 2023, estimated DelveInsight

DelveInsight’s “Primary Hyperoxaluria Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Primary Hyperoxaluria, historical and forecasted epidemiology as well as the Primary Hyperoxaluria market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

Discover Key Insights into the Primary Hyperoxaluria Market with DelveInsight’s In-Depth Report @ Primary Hyperoxaluria Market Size

 

Key Takeaways from Primary Hyperoxaluria Market Report

  • In the assessment done by DelveInsight, the estimated total prevalent cases of Primary Hyperoxaluria in the 7MM were ~12 thousand in 2023.
  • The highest total diagnosed prevalent cases of Primary Hyperoxaluria were accounted by US in 2023 (~2 thousand), which are expected to show a rise in the future.
  • Among the European countries, the UK had the highest diagnosed prevalent cases of Primary Hyperoxaluria with ~220 cases, followed by Germany, which had prevalent population of ~188 in 2023. On the other hand, Spain had the lowest prevalent population (~100 cases).
  • Japan had the fewest total diagnosed prevalent cases of Primary Hyperoxaluria in 2023, accounting for approximately 2.5% of the cases in 7MM.
  • In 2023, in the US, the age-specific diagnosed prevalent cases of Primary Hyperoxaluria were highest for age group 0–4 (~780 cases), followed by 5–9 (~470 cases). The lowest number of cases was in the 15–19 years age group.
  • In 2023, in Japan, the type-specific diagnosed prevalent cases of Primary Hyperoxaluria were highest for Primary Hyperoxaluria Type 1 (~64 cases), followed by Primary Hyperoxaluria Type 2, Primary Hyperoxaluria Type 3 and unclassified.
  • The leading Primary Hyperoxaluria Companies such as Dicerna Pharmaceuticals, Inc., Allena Pharmaceuticals, Biocodex, Alnylam Pharmaceuticals, Biocodex, Dicerna Pharmaceuticals, and others
  • Promising Primary Hyperoxaluria Therapies such as Nedosiran (DCR-PHXC), ALLN-177, Stiripentol, Lumasiran, stiripentol (Diacomit), DCR-PHXC, and others

 

Navigate the complexities of the Primary Hyperoxaluria Market: gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Primary Hyperoxaluria Market Forecast. Click here to get more insights @ Primary Hyperoxaluria Treatment Market

 

Primary Hyperoxaluria Epidemiology Segmentation in the 7MM

  • Prevalent Cases of Primary Hyperoxaluria in the 7MM
  • Diagnosed Prevalent Cases of Primary Hyperoxaluria in the 7MM
  • Gender-specific Cases of Diagnosed Prevalent Cases of Primary Hyperoxaluria in the 7MM
  • Age-specific Cases of Diagnosed Prevalent Cases of Primary Hyperoxaluria in the 7MM
  • Type-specific Cases of Diagnosed Prevalent Cases of Primary Hyperoxaluria in the 7MM

 

Download the report to understand which factors are driving Primary Hyperoxaluria epidemiology trends @ Primary Hyperoxaluria Prevalence

 

 

Primary Hyperoxaluria Marketed Drugs

  • OXLUMO (Lumasiran/ALN-GO1): Alnylam Pharma

Lumasiran (formerly ALN-GO1) developed by Alnylam Pharma, approved in Year 2020, is a subcutaneously administered, RNAi therapeutic targeting glycolate oxidase (GO). Lumasiran is designed to reduce hepatic levels of GO enzyme (encoded by HAO1), thereby depleting substrate necessary for oxalate production, which directly contributes to the pathophysiology of Primary Hyperoxaluria type 1.

 

  • RIVFLOZA (nedosiran/DCR-PHXC): Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceutical’s Nedosiran (formerly referred to as DCR-PHXC) is an advanced therapy utilized with the company’s GalXC technology to treat patients with Primary Hyperoxaluria. It was approved in Year 2023. It inhibits the lactate dehydrogenase (LDH) enzyme in the final common step of this pathway and thereby attempts to prevent this overproduction of oxalate. This LDH enzyme inhibition occurs specifically in the liver due to the incorporation of GalNAc targeting ligands in nedosiran that bind specifically to the asialoglycoprotein receptors (ASGPR) on hepatic cell surfaces.

 

Primary Hyperoxaluria Emerging Drugs

  • Stiripentol (Diacomit): Biocodex

Stiripentol is an anticonvulsant drug used in treating epilepsy as an adjunct therapy along with Clobazam and Valproic acid. This drug is currently approved in the US, Canada, and European countries as oral tablets marketed as Diacomit. Unrelated to other anticonvulsants, stiripentol belongs to the group of aromatic allylic alcohols and may potentiate the effect of other antiepileptic drugs (AEDs) due to pharmacokinetic interactions. It elevates gamma-aminobutyric acid (GABA) levels, a major inhibitory neurotransmitter that regulates electrical activity in the central nervous system.

 

Get In-Depth Knowledge on Primary Hyperoxaluria Market Trends and Forecasts with DelveInsight @ Primary Hyperoxaluria Treatment Market

 

Primary Hyperoxaluria Market Outlook

The global burden of Primary Hyperoxaluria has increased over the years. Among the seven major markets, the United States has reported having maximum diagnosed prevalent cases of Primary Hyperoxaluria. Though the prevalence of Primary Hyperoxaluria is high across the US, the condition is often misdiagnosed, ultimately leading to a lower treatable pool (when compared to the total prevalent population of the disease) that contributes to the market size of Primary Hyperoxaluria.

 

Primary Hyperoxaluria Treatment Market

The Primary Hyperoxaluria treatment usually started with citrates, vitamin B6, and hyperhydration. After that, iRNA therapies begin. Patients with advanced kidney failure go for kidney transplantation. Transplantation methods depend on the type of primary hyperoxaluria and the particular patient, but combined liver and kidney transplantation is the method of choice in patients with PH1, and isolated kidney transplantation is the preferred method with PH2.

 

Gain a strategic edge in the Primary Hyperoxaluria Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Primary Hyperoxaluria Market Forecast. Click here to lead in advancements @ Primary Hyperoxaluria Clinical Trials Assessment

 

Scope of the Primary Hyperoxaluria Market Report

  • Study Period: 2020–2034
  • Coverage: 7MM
  • Primary Hyperoxaluria Companies: Dicerna Pharmaceuticals, Inc., Allena Pharmaceuticals, Biocodex, Alnylam Pharmaceuticals, Biocodex, Dicerna Pharmaceuticals, and others
  • Primary Hyperoxaluria Therapies: Nedosiran (DCR-PHXC), ALLN-177, Stiripentol, Lumasiran, stiripentol (Diacomit), DCR-PHXC, and others
  • Primary Hyperoxaluria Therapeutic Assessment: Primary Hyperoxaluria current marketed and Primary Hyperoxaluria emerging therapies
  • Primary Hyperoxaluria Market Dynamics: Primary Hyperoxaluria market drivers and Primary Hyperoxaluria market barriers
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Primary Hyperoxaluria Unmet Needs, KOL’s views, Analyst’s views, Primary Hyperoxaluria Market Access and Reimbursement

 

Table of Contents

1. Primary Hyperoxaluria Market Report Introduction

2. Executive Summary for Primary Hyperoxaluria

3. SWOT analysis of Primary Hyperoxaluria

4. Primary Hyperoxaluria Patient Share (%) Overview at a Glance

5. Primary Hyperoxaluria Market Overview at a Glance

6. Primary Hyperoxaluria Disease Background and Overview

7. Primary Hyperoxaluria Epidemiology and Patient Population

8. Country-Specific Patient Population of Primary Hyperoxaluria

9. Primary Hyperoxaluria Current Treatment and Medical Practices

10. Primary Hyperoxaluria Unmet Needs

11. Primary Hyperoxaluria Emerging Therapies

12. Primary Hyperoxaluria Market Outlook

13. Country-Wise Primary Hyperoxaluria Market Analysis (2020–2034)

14. Primary Hyperoxaluria Market Access and Reimbursement of Therapies

15. Primary Hyperoxaluria Market Drivers

16. Primary Hyperoxaluria Market Barriers

17. Primary Hyperoxaluria Appendix

18. Primary Hyperoxaluria Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Primary Hyperoxaluria Therapeutics Market Size in the 7MM was ~USD 316 million in 2023, estimated DelveInsight

Primary Biliary Cholangitis Therapeutics Market Size in the 7MM was over further expected to increase by 2034, estimates DelveInsight

DelveInsight’s “Primary Biliary Cholangitis Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of the Primary Biliary Cholangitis, historical and forecasted epidemiology as well as the Primary Biliary Cholangitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Discover which therapies are expected to grab the Primary Biliary Cholangitis Market Share @ Primary Biliary Cholangitis Market Outlook

 

Key Takeaways form the Primary Biliary Cholangitis Market Report

  • DelveInsight’s forecasting report of PBC includes the Epidemiology analysis and forecast of the US, EU4 and the UK, and Japan. As per our analysis, the US had the highest diagnosed prevalent cases of PBC in 2023, which are expected to rise, at a decent CAGR during the forecasted period (2024–2034).
  • In 2023, among EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Germany accounted for the highest number of diagnosed prevalent cases of PBC i.e. around 34 thousand cases which is expected to increase by 2034.
  • The incidence of PBC rises with age, and is particularly higher among individuals aged 40 to 70 years. Our estimates for 2023 indicate a distribution of cases by age groups: approximately 14 thousand cases were observed in individuals under 40 years old, with numbers increasing steadily with age. The highest number of cases, totaling 87 thousand, occurred in the 40–70 age bracket, while 43 thousand cases were reported in individuals aged 70 and above in the US.
  • Our analysis indicates a higher prevalence of PBC among females compared to males, with distribution rates of 82% and 18% respectively, in the US in 2023.
  • The leading Primary Biliary Cholangitis Companies such as Intercept Pharmaceuticals, CymaBay Therapeutics, Genfit, Genkyotex SA, Zydus Cadila, Cara Therapeutics, HighTide Therapeutics, Albireo, GlaxoSmithKline, and others.
  • Promising Primary Biliary Cholangitis Therapies such as Elafibranor, Saroglitazar Magnesium, CNP-104, Setanaxib, Seladelpar, Volixibat, Bezafibrate, EP547, Linerixibat, and others.

 

Navigate the complexities of the Primary Biliary Cholangitis Market: gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Primary Biliary Cholangitis Market Forecast. Click here to get more insights @ Primary Biliary Cholangitis Treatment Market

 

Primary Biliary Cholangitis Epidemiology Segmentation in the 7MM

  • Total Primary Biliary Cholangitis Diagnosed Prevalent Cases
  • Primary Biliary Cholangitis Gender-specific Cases
  • Primary Biliary Cholangitis Age-specific Cases

 

Download the report to understand which factors are driving Primary Biliary Cholangitis Epidemiology trends @ Primary Biliary Cholangitis Prevalence

 

Primary Biliary Cholangitis Marketed Drugs

 

  • OCALIVA: Intercept Pharmaceuticals

OCALIVA offers a novel treatment approach for PBC by targeting FXR and has shown efficacy in reducing ALP levels and improving outcomes for patients who have not responded to or cannot tolerate UDCA, highlighting its significance as an alternative therapy in the management of PBC. OCALIVA has received accelerated approval from the FDA for the treatment of PBC, demonstrating its potential to address serious conditions and providing earlier patient access to promising new drugs while confirmatory trials are ongoing.

 

Primary Biliary Cholangitis Emerging Drugs

 

  • Seladelpar: CymaBay Therapeutics

Seladelpar, developed by CymaBay Therapeutics, is an oral, selective peroxisome proliferator-activated receptor (PPAR) delta agonist aimed at treating primary biliary cholangitis (PBC). It regulates crucial metabolic and liver disease pathways, impacting bile acid synthesis, inflammation, fibrosis, and lipid metabolism. Clinical studies demonstrate its efficacy in reducing biomarkers associated with adverse outcomes in PBC, alongside improving pruritus. Unlike other PPAR agonists, seladelpar acts on various liver cell types, uniquely affecting PBC pathobiology. It has garnered FDA Breakthrough Therapy Designation and EMA Priority Medicines (PRIME) status, with an NDA submitted to the FDA for PBC treatment, underscoring its promising potential and regulatory recognition.

 

Get In-Depth Knowledge on Primary Biliary Cholangitis Market Trends and Forecasts with DelveInsight @ Primary Biliary Cholangitis Treatment Market

 

Primary Biliary Cholangitis Treatment Market

Treatment objectives aim to decelerate the advancement of the disease and alleviate associated symptoms such as itching, osteoporosis, and sicca syndrome. Liver transplantation stands as the singular life-saving procedure available. Ursodeoxycholic acid (UDCA) stands as the primary medication employed to impede disease progression. Patients in the initial stages of the disease witness clinical, biochemical, and histological enhancements. Studies indicate that UDCA postpones the necessity for transplantation and prolongs life. However, its effectiveness in later stages, particularly in cases of cirrhosis, remains uncertain.

 

Primary Biliary Cholangitis Companies

Intercept Pharmaceuticals, CymaBay Therapeutics, Genfit, Genkyotex SA, Zydus Cadila, Cara Therapeutics, HighTide Therapeutics, Albireo, GlaxoSmithKline, and others.

 

Scope of the Primary Biliary Cholangitis Market Report

  • Coverage- 7MM
  • Study Period- 2020-2034
  • Primary Biliary Cholangitis Companies- Intercept Pharmaceuticals, CymaBay Therapeutics, Genfit, Genkyotex SA, Zydus Cadila, Cara Therapeutics, HighTide Therapeutics, Albireo, GlaxoSmithKline, and others.
  • Primary Biliary Cholangitis Therapies- Elafibranor, Saroglitazar Magnesium, CNP-104, Setanaxib, Seladelpar, Volixibat, Bezafibrate, EP547, Linerixibat, and others.
  • Primary Biliary Cholangitis Market Dynamics: Primary Biliary Cholangitis Market Drivers and Barriers
  • Primary Biliary Cholangitis Unmet Needs, KOL’s views, Analyst’s views, Primary Biliary Cholangitis Market Access and Reimbursement

 

Gain a strategic edge in the Primary Biliary Cholangitis Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Primary Biliary Cholangitis Market Forecast. Click here to lead in advancements @ Primary Biliary Cholangitis Clinical Trials Assessment

 

Table of Content

1. Key Insights

2. Executive Summary of Primary Biliary Cholangitis

3. Competitive Intelligence Analysis for Primary Biliary Cholangitis

4. Primary Biliary Cholangitis: Market Overview at a Glance

5. Primary Biliary Cholangitis: Disease Background and Overview

6. Patient Journey

7. Primary Biliary Cholangitis Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Primary Biliary Cholangitis Unmet Needs

10. Key Endpoints of Primary Biliary Cholangitis Treatment

11. Primary Biliary Cholangitis Marketed Products

12. Primary Biliary Cholangitis Emerging Therapies

13. Primary Biliary Cholangitis: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Primary Biliary Cholangitis Market Outlook

16. Access and Reimbursement Overview of Primary Biliary Cholangitis

17. Primary Biliary Cholangitis KOL Views

18. Primary Biliary Cholangitis Market Drivers

19. Primary Biliary Cholangitis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Primary Biliary Cholangitis Therapeutics Market Size in the 7MM was over further expected to increase by 2034, estimates DelveInsight